|Mr. Anthony S. Marucci M.B.A.||Co-Founder, Pres, CEO & Director||873.75k||N/A||55|
|Dr. Tibor Keler Ph.D.||Founder, Chief Scientific Officer and Exec. VP||552.71k||N/A||58|
|Dr. Thomas Davis M.D.||Chief Medical Officer and Exec. VP||581.42k||N/A||53|
|Ms. Elizabeth Crowley||Chief Product Devel. Officer and Sr. VP||423.2k||N/A||45|
|Mr. Sam Martin||CFO & Sr. VP||N/A||N/A||N/A|
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 2. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 1; Compensation: 6.